AIDS

Article	Citations
Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study	128
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis	112
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV	75
Risk of adverse coronavirus disease 2019 outcomes for people living with HIV	74
The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture	68
Impaired antibody response to COVID-19 vaccination in advanced HIV infection	66
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection	63
HIV in Iran: onset, responses, and future directions	53
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes	50
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment	49
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents	40
Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM	39
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV	38
Worldwide relative smoking prevalence among people living with and without HIV	37
Comparison of dementia risk after age 50 between individuals with and without HIV infection	37
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen	37
Community-based delivery of HIV treatment in Zambia: costs and outcomes	37
Is tenofovir disoproxil fumarate associated with weight loss?	35
Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection	34
Increasing preexposure prophylaxis use and ‘net prevention coverage’ in behavioural surveillance of Australian gay and bisexual men	33
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV	33
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era	30
Characteristics and clinical manifestations of monkeypox among people with and without HIV in the United States: a retrospective cohort	29
Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed	28
HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM	27

High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV – but HIV viremia matters?	26
Circulating extracellular vesicles as new inflammation marker in HIV infection	25
Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV	24
SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment	24
Household wealth and HIV incidence over time, rural Uganda, 1994–2018	23
Impact of long-acting therapies on the global HIV epidemic	22
Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens	22
The shifting age distribution of people with HIV using antiretroviral therapy in the United States	22
Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis	21
Association of HIV infection with outcomes among adults hospitalized with COVID-19	21
Curable sexually transmitted infections among women with HIV in sub-Saharan Africa	20
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV	20
Accuracy of self-reported HIV-testing history and awareness of HIV-positive status in four sub-Saharan African countries	20
Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV	20
COVID-19 vaccine immunogenicity in people with HIV	20
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain	20
Structural determinants of HIV/STI prevalence, HIV/STI/sexual and reproductive health access, and condom use among immigrant sex workers globally	20
An updated meta-analysis on the association between HIV infection and COVID-19 mortality	20
Viral suppression during COVID-19 among people with HIV experiencing homelessness in a low-barrier clinic-based program	20
HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptional activity	19
Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy	19
The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy	19
Telemedicine and visit completion among people with HIV during the coronavirus disease 2019 pandemic compared with prepandemic	19
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy	18
Clinic and care: associations with adolescent antiretroviral therapy adherence in a prospective cohort in South Africa	18
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV	18
Progress toward HIV elimination goals: trends in and projections of annual HIV testing and condom use in Africa	18
The COVID-19 pandemic as a catalyst for differentiated care models to end the HIV epidemic in the United States: applying lessons from high-burden settings	18
Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia	18
Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV	17
SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV	17
Using longitudinal genetic-network study to understand HIV treatment-as-prevention	17
Comparison of dementia incidence and prevalence between individuals with and without HIV infection in primary care from 2000 to 2016	17
Increase in HIV incidence in women exposed to rape	17
Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa	17
Long-term persistence of transcriptionally-active “defective” HIV-1 proviruses: Implications for persistent immune activation during antiretroviral therapy	17
Higher prevalence of stunting and poor growth outcomes in HIV-exposed uninfected than HIV-unexposed infants in Kenya	17
Effects of anticholinergic medication use on brain integrity in persons living with HIV and persons without HIV	17
Impact of HIV infection on baseline characteristics and survival of women with breast cancer	17
Declines in HIV prevalence in female sex workers accessing an HIV treatment and prevention programme in Nairobi, Kenya over a 10-year period	17
Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014–2019	16
Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV	16
Utilizing electronic health record data to understand comorbidity burden among people living with HIV: a machine learning approach	16
Weight gain stopping/switch rules for antiretroviral clinical trials	16
Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors	16
Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era	16
Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV	16
Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing	16
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV	16
Employing telehealth within HIV care: advantages, challenges, and recommendations	15

First pharmacokinetic data of bictegravir in pregnant women living with HIV	15
Novel population-level proxy measures for suboptimal HIV preexposure prophylaxis initiation and persistence in the USA	15
Estimated time from HIV infection to diagnosis and diagnosis to first viral suppression during 2014–2018	15
Children who are HIV-exposed and uninfected: evidence for action	15
Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment	15
HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition	15
A systematic review of early adoption of implementation science for HIV prevention or treatment in the United States	14
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1	14
Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes	14
False-positive HIV screening test in a patient with pulmonary embolism because of severe acute respiratory syndrome coronavirus 2 infection	14
The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum	14
Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine	14
Longitudinal association between intimate partner violence and viral suppression during pregnancy and postpartum in South African women	14
Low CD4+ cell count nadir exacerbates the impacts of APOE ε4 on functional connectivity and memory in adults with HIV	14
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection	14
Differential impact of antiretroviral therapy initiated before or during pregnancy on placenta pathology in HIV-positive women	14
Interventions to improve daily medication use among adolescents and young adults: what can we learn for youth pre-exposure prophylaxis services?	14
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV	14
Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa	14
Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition	14
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoprox	14
Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States	13
Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation	13
Assessing comorbidities and survival in HIV-infected and uninfected matched Medicare enrollees	13
Losartan to reduce inflammation and fibrosis endpoints in HIV disease	13
Incidence of HIV-positive admission and inpatient mortality in Malawi (2012–2019)	13
From policy to practice: uptake of pre-exposure prophylaxis among adolescent girls and young women in United States President's Emergency Plan for AIDS Relief-supported countries, 2017–2020	13
The other side of screening: predictors of treatment and follow-up for anal precancers in a large health system	13
Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression	13
Impact of the coronavirus disease 2019 pandemic on prescriptions for antiretroviral drugs for HIV treatment in the United States, 2019–2021	13
Modeling the cost-effectiveness of point-of-care platforms for infant diagnosis of HIV in sub-Saharan African countries	13
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa	13
A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV	13
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc	13
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate	13
Achieving maternal viral load suppression for elimination of mother-to-child transmission of HIV in South Africa	13
Multimorbidity networks associated with frailty among middle-aged and older people with HIV	13
Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis	12
Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV	12
Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV	12
Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV	12
Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy	12
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens	12
Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multi-country longitudinal cohort analysis	12
Trends in diabetes incidence and associated risk factors among people with HIV in the current treatment era	12
A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi sarcoma	12
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series	12
Application of machine-learning techniques in classification of HIV medical care status for people living with HIV in South Carolina	12
Cognitive trajectories after treatment in acute HIV infection	12
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy	12
Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy	12
Prevalence and risk factors of frailty among adults living with HIV aged 70 years or older	12
Ambient air pollution is associated with vascular disease in Ugandan HIV-positive adolescents	12
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV	12
Aging, trends in CD4+/CD8+ cell ratio, and clinical outcomes with persistent HIV suppression in a dynamic cohort of ambulatory HIV patients	12
Common pathogen-associated molecular patterns induce the hyper-activation of NLRP3 inflammasome in circulating B lymphocytes of HIV-infected individuals	12
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients	12
Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression	12
Strategies to improve HIV care outcomes for people with HIV who are out of care	12
HIV/AIDS and aging: the new frontier for HIV/AIDS research and care	11
Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine	11
Circulating CD4+ TEMRA and CD4+ CD28− T cells and incident diabetes among persons with and without HIV	11
Syndemics and preexposure prophylaxis are independently associated with rectal immune dysregulation in sexual minority men	11
The association of exposure to DREAMS on sexually acquiring or transmitting HIV amongst adolescent girls and young women living in rural South Africa	11
Mathematical modelling of the influence of serosorting on the population-level HIV transmission impact of pre-exposure prophylaxis	11
Immunogenicity, effectiveness and safety of SARS-CoV-2 vaccination in people living with HIV: A systematic review and meta-analysis	11
Global estimates for the lifetime cost of managing HIV	11
Identifying HIV-related digital social influencers using an iterative deep learning approach	11
Antiretroviral therapy-treated HIV-infected adults with coronary artery disease are characterized by a distinctive regulatory T-cell signature	11
Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/hepatitis C virus coinfections	11
Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals	11
Potential reduction in female sex workers’ risk of contracting HIV during coronavirus disease 2019	11
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis	11
The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences	11
HIV-1 infection of the kidney: mechanisms and implications	11
Improved virologic outcomes in postpartum women living with HIV referred to differentiated models of care	11
Improving adherence to daily preexposure prophylaxis among MSM in Amsterdam by providing feedback via a mobile application	11
Monocyte activation in persons living with HIV and tuberculosis coinfection	10
Preterm birth and severe morbidity in hospitalized neonates who are HIV exposed and uninfected compared with HIV unexposed	10
HIV-associated wasting prevalence in the era of modern antiretroviral therapy	10

Differences in HIV clinical outcomes amongst heterosexuals in the United Kingdom by ethnicity	10
Adolescent HIV-related behavioural prediction using machine learning: a foundation for precision HIV prevention	10
High-risk human papillomavirus test in anal smears: can it optimize the screening for anal cancer?	10
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I	10
Using phylogenetic surveillance and epidemiological data to understand the HIV-1 transmission dynamics in French Guiana	10
Distinct forms of migration and mobility are differentially associated with HIV treatment adherence	10
Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands	10
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria	10
Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy	10
High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2	10
Severe acute respiratory syndrome coronavirus-2 antibody prevalence in people with and without HIV in rural Western Kenya, January to March 2020	10
Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure	10
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period	10
Accelerating adolescent HIV research in low-income and middle-income countries: evidence from a research consortium	10
Trends in HIV prevalence by self-report among MSM diagnosed and reported with gonorrhea in six United States jurisdictions from 2010 to 2019	10
Interactive digital interventions for prevention of sexually transmitted HIV	10
Association between inflammatory biomarker profiles and cardiovascular risk in individuals with and without HIV	10
Assessing layered HIV prevention programming: optimizing outcomes for adolescent girls and young women	10
Predictors of secondary HIV transmission risk in a cohort of adolescents living with HIV in South Africa	10
Longitudinal changes in epigenetic age in youth with perinatally acquired HIV and youth who are perinatally HIV-exposed uninfected	10
Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV	10
Prevalence of nonalcoholic fatty liver disease using noninvasive techniques among children, adolescents, and youths living with HIV	10
Increased risk of false-positive HIV ELISA results after COVID-19	9
Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades	9
COVID-19 in people with HIV in the Netherlands, the ATHENA cohort study	9
Tenofovir-based PrEP for COVID-19: an untapped opportunity?	9
Growth deficits in antiretroviral and HIV-exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months of age	9
The interrelationship of smoking, CD4+ cell count, viral load and cancer in persons living with HIV	9
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence	9
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries	9
Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens	9
Interleukin-17A is associated with flow-mediated dilation and interleukin-4 with carotid plaque in persons with HIV	9
Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV	9
Risk factors and outcomes of HIV-associated stroke in Zambia	9
Effect of HIV stigma on depressive symptoms, treatment adherence, and viral suppression among youth with HIV	9
Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc	9
Lipidome association with vascular disease and inflammation in HIV+ Ugandan children	9
Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda	9
Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization	9
Changes in HIV preexposure prophylaxis prescribing in Australian clinical services following COVID-19 restrictions	9
Sex modulates the association between inflammation and coronary atherosclerosis among older Ugandan adults with and without HIV	9
Minimal detection of cerebrospinal fluid escape after initiation of antiretroviral therapy in acute HIV-1 infection	9
The global burden of cognitive impairment in people with HIV	9
Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis	8
Results of a cluster randomized trial testing the systems analysis and improvement approach to increase HIV testing in family planning clinics	8
Monitoring socioeconomic inequalities across HIV knowledge, attitudes, behaviours and prevention in 18 sub-Saharan African countries	8
HIV, hepatitis C virus and risk of new-onset left ventricular dysfunction in women	8
Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria	8
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide	8
Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa	8
Hepatitis delta in patients hospitalized in Spain (1997–2018)	8
Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV	8
Outcomes following severe acute respiratory syndrome coronavirus 2 infection among individuals with and without HIV in Denmark	8
Impact of coronavirus disease 2019 epidemics on prevention and care for HIV and other sexually transmitted infections	8
Mechanisms of systemic low-grade inflammation in HIV patients on long-term suppressive antiretroviral therapy: the inflammasome hypothesis	8
Cervical cancer incidence stratified by age in women with HIV compared with the general population in the United States, 2002–2016	8
The war refugees from Ukraine: an HIV epidemic is fleeing as well	8
Power of Big Data in ending HIV	8
Redistribution of brain glucose metabolism in people with HIV after antiretroviral therapy initiation	8
Using a machine learning approach to explore predictors of healthcare visits as missed opportunities for HIV diagnosis	8
Years of life lost to cancer among the US HIV population, 2006–2015	8
Intersectional stigmas are associated with lower viral suppression rates and antiretroviral therapy adherence among women living with HIV	8
SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy	8
Impact of a community-wide combination HIV prevention intervention on knowledge of HIV status among adolescents	8
Promoting antiretroviral therapy adherence habits: a synthesis of economic and psychological theories of habit formation	8
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir	8
Industrial mining and HIV risk: evidence from 39 mine openings across 16 countries in sub-Saharan Africa	8
Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana	8
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV	8
Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts	8
Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya	8
Persistently lower bone mass and bone turnover among South African children living with well controlled HIV	8
Real world use of dolutegravir two drug regimens	8
Estimation of HIV incidence from analysis of HIV prevalence patterns among female sex workers in Zimbabwe	8
Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women	8
Unmet needs for HIV ancillary care services by healthcare coverage and Ryan White HIV/AIDS program assistance	8
Differential patterns of postmigration HIV-1 infection acquisition among Portuguese immigrants of different geographical origins	8
The utility of olfactory function in distinguishing early-stage Alzheimer's disease from HIV-associated neurocognitive disorders	8
Plasma biomarker factors associated with neurodevelopmental outcomes in children with perinatal HIV infection and controlled viremia	8
Host variation in type I interferon signaling genes (MX1), C–C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservo	8
Distinct effects of treatment with two different interferon-alpha subtypes on HIV-1-associated T-cell activation and dysfunction in humanized mice	8
Inferring population HIV incidence trends from surveillance data of recent HIV infection among HIV testing clients	7
Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya	7
Identifying influential neighbors in social networks and venue affiliations among young MSM: a data science approach to predict HIV infection	7
Sex differences in cytokine profiles during suppressive antiretroviral therapy	7
Failure to restore CD4+ cell count associated with infection-related and noninfection-related cancer	7
A prospective study on adverse childhood experiences and HIV-related risk among adolescents in Malawi	7
DREAMS impact on HIV status knowledge and sexual risk among cohorts of young women in Kenya and South Africa	7
HIV viral load and pregnancy loss: results from a population-based cohort study in rural KwaZulu-Natal, South Africa	7
Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus	7
Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus	7
Soluble biomarkers associated with chronic lung disease in older children and adolescents with perinatal HIV infection	7
Routine programmatic data show a positive population-level impact of HIV self-testing: the case of Côte d’Ivoire and implications for implementation	7
HIV in the Russian Federation: mortality, prevalence, risk factors, and current understanding of sexual transmission	7
The evolution of DREAMS: using data for continuous program improvement	7